DK3380119T3 - Fmdv- og e2-fusionsproteiner og anvendelser deraf - Google Patents

Fmdv- og e2-fusionsproteiner og anvendelser deraf Download PDF

Info

Publication number: DK3380119T3
Authority: DK; Denmark
Prior art keywords: fmdv; fusion proteins; fusion; proteins
Prior art date: 2015-11-23

Application number

DK16813258.7T

Other languages

English (en)

Inventor

Jean-Christophe Audonnet

Frederic Reynard

Natalia Bomchil

Cecile Sigoillot-Claude

Original Assignee

Boehringer Ingelheim Animal Health Usa Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-11-23

Filing date

2016-11-16

Publication date

2021-11-15

2016-11-16 Application filed by Boehringer Ingelheim Animal Health Usa Inc filed Critical Boehringer Ingelheim Animal Health Usa Inc

2021-11-15 Application granted granted Critical

2021-11-15 Publication of DK3380119T3 publication Critical patent/DK3380119T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/135—Foot- and mouth-disease virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32171—Demonstrated in vivo effect

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Zoology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK16813258.7T 2015-11-23 2016-11-16 Fmdv- og e2-fusionsproteiner og anvendelser deraf DK3380119T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562259043P	2015-11-23	2015-11-23
PCT/US2016/062367 WO2017091418A1 (en)	2015-11-23	2016-11-16	Fmdv and e2 fusion proteins and uses thereof

Publications (1)

Publication Number	Publication Date
DK3380119T3 true DK3380119T3 (da)	2021-11-15

Family

ID=57570585

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK16813258.7T DK3380119T3 (da)	2015-11-23	2016-11-16	Fmdv- og e2-fusionsproteiner og anvendelser deraf

Country Status (19)

Country	Link
US (2)	US9913891B2 (da)
EP (2)	EP3539566A1 (da)
JP (2)	JP6797206B2 (da)
KR (1)	KR102153303B1 (da)
CN (1)	CN108367067B (da)
AR (1)	AR106792A1 (da)
AU (1)	AU2016361305B2 (da)
BR (1)	BR112018010494A8 (da)
CA (1)	CA3006078A1 (da)
DK (1)	DK3380119T3 (da)
ES (1)	ES2899230T3 (da)
MA (3)	MA49414A (da)
MX (1)	MX382535B (da)
NZ (1)	NZ743236A (da)
RU (1)	RU2714428C2 (da)
TW (1)	TWI744260B (da)
UY (1)	UY36995A (da)
WO (1)	WO2017091418A1 (da)
ZA (1)	ZA201803390B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3824906A1 (en)	2016-12-21	2021-05-26	Amgen Inc.	Anti-tnf alpha antibody formulations
MX2020009720A (es) *	2018-03-19	2021-01-08	Boehringer Ingelheim Vetmedica China Co Ltd	Virus recombinante capaz de expresar de manera estable proteinas objetivo.
CN109187993B (zh) *	2018-09-13	2020-06-16	中国农业科学院兰州兽医研究所	一种口蹄疫A型病毒sIgA抗体ELISA检测试剂盒及其应用
CN111233984B (zh) *	2018-11-29	2022-08-12	普莱柯生物工程股份有限公司	一种o型口蹄疫病毒样颗粒抗原、及其疫苗组合物、制备方法和应用
CN110028160B (zh) *	2019-01-24	2022-04-29	暨南大学	一种功能性微藻固定化材料的制备方法及其应用
WO2020263062A1 (ko) *	2019-06-28	2020-12-30	(주)플럼라인생명과학	구제역 바이러스 백신 조성물
CN115925907B (zh) *	2022-09-19	2025-08-05	北京田园奥瑞生物科技有限公司	一种羊口蹄疫纳米抗体及其在精液保藏检测中的应用
CN119505021B (zh) *	2025-01-20	2025-04-18	内蒙古和讯生物科技有限公司	一种重复结构单元重组蛋白cpE2及其制备方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2909462A (en)	1955-12-08	1959-10-20	Bristol Myers Co	Acrylic acid polymer laxative compositions
US5505941A (en)	1981-12-24	1996-04-09	Health Research, Inc.	Recombinant avipox virus and method to induce an immune response
CA1247080A (en)	1983-03-08	1988-12-20	Commonwealth Serum Laboratories Commission	Antigenically active amino acid sequences
EP0173552B1 (en)	1984-08-24	1991-10-09	The Upjohn Company	Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en)	1985-12-18	1990-11-06	Ciba-Geigy Corporation	Deoxyribonucleic acid segment from a virus
US4963481A (en)	1985-12-18	1990-10-16	Genetics Institute Inc	Promoter system
EP0260148A3 (en)	1986-09-12	1989-06-07	Genentech, Inc.	Improved recombinant expression method, vector and transformed cells
DE3743138A1 (de)	1987-12-18	1989-09-14	Mayr Christian Gmbh & Co Kg	Schleifringlose, elektromagnetische ueberlastkupplung
JP3602530B2 (ja)	1991-03-07	2004-12-15	ヴァイロジェネティクスコーポレイション	遺伝子操作したワクチン菌株
CA2214029A1 (en)	1995-04-25	1996-10-31	Magda Marquet	Single-vial formulations of dna/lipid complexes
US5846946A (en)	1996-06-14	1998-12-08	Pasteur Merieux Serums Et Vaccins	Compositions and methods for administering Borrelia DNA
FR2751225B1 (fr)	1996-07-19	1998-11-27	Rhone Merieux	Formule de vaccin polynucleotidique aviaire
FR2751224B1 (fr)	1996-07-19	1998-11-20	Rhone Merieux	Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
FR2751229B1 (fr)	1996-07-19	1998-11-27	Rhone Merieux	Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
FR2751228B1 (fr)	1996-07-19	1998-11-20	Rhone Merieux	Vaccin polynucleotidique bovin pour voie intradermique
FR2751227B1 (fr)	1996-07-19	1998-11-27	Rhone Merieux	Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751226B1 (fr)	1996-07-19	1998-11-27	Rhone Merieux	Formule de vaccin polynucleotidique contre les pathologies du cheval
EP0930893B1 (en)	1996-10-11	2005-04-13	The Regents of The University of California	Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
PL337583A1 (en)	1997-06-30	2000-08-28	Rhone Poulenc Rorer Sa	Improved method of transferring nucleic acid to a striated muscle and connection enabling accomplishment of this method
FR2778858B1 (fr)	1998-05-20	2000-06-16	Oreal	Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique
FR2801607B1 (fr)	1999-11-26	2001-12-28	Merial Sas	Pneumovirus du canard et vaccins correspondants
GB9929151D0 (en) *	1999-12-09	2000-02-02	Univ Cambridge Tech	Peptide and polypeptide display
US6852705B2 (en)	2000-01-21	2005-02-08	Merial	DNA vaccines for farm animals, in particular bovines and porcines
UA84024C2 (ru)	2003-07-24	2008-09-10	Мериал Лимитед	Новые вакцинные композиции, которые содержат эмульсию типа "масло в воде"
US7527960B2 (en)	2004-06-25	2009-05-05	Merial Limited	Avipox recombinants expressing foot and mouth disease virus genes
US7691368B2 (en)	2005-04-15	2010-04-06	Merial Limited	Vaccine formulations
US20070160628A1 (en) *	2005-08-31	2007-07-12	Birkett Ashley J	Stabilized virus-like particles and epitope display systems
EP2316480A1 (en) *	2006-03-17	2011-05-04	Indian Immunologicals Ltd	Chimeric tymovirus-like particles
CN101293098A (zh) *	2007-04-28	2008-10-29	北京迪威华宇生物技术有限公司	一种重组牛o型口蹄疫病毒融合蛋白疫苗
SG179037A1 (en)	2009-09-10	2012-04-27	Merial Ltd	New vaccine formulations comprising saponin-containing adjuvants
EP2545067B1 (en) *	2010-03-12	2016-11-30	Merial, Inc.	Bluetongue virus recombinant vaccines and uses thereof
RU2467014C2 (ru) *	2010-12-06	2012-11-20	Учреждение Российской академии наук Центр "Боинженерия" РАН	Полиэпитопный белок, нуклеотидная последовательность, кодирующая полиэпитопный белок, плазмида с последовательностью, кодирующей полиэпитопный белок, и препарат полиэпитопного белка для индукции иммунного ответа против вируса ящура
KR20150084993A (ko) *	2012-11-16	2015-07-22	유나이티드 바이오메디칼 인크.	구제역 (fmd)에 대한 합성 펩티드-기재 응급 백신
EP2928491B1 (en) *	2012-12-05	2018-11-21	TheVax Genetics Vaccine Co., Ltd.	Fusion proteins for use as immunogenic enhancers for inducing antigen-specific t cell responses
CN103305542B (zh) *	2013-06-25	2015-03-11	江苏省农业科学院	一种重组噬菌体双表达载体及应用
US10744199B2 (en) *	2013-10-11	2020-08-18	The Usa, As Represented By The Secretary, Dept. Of Health And Human Services	Epstein-Barr virus vaccines
CN103933581A (zh) *	2014-05-04	2014-07-23	贵州大学	一种基于csf-fmd二联基因工程疫苗的制备方法
AP2017009834A0 (en)	2014-09-23	2017-03-31	Merial Inc	Fmdv recombinant vaccines and uses thereof

2016
- 2016-11-16 KR KR1020187017812A patent/KR102153303B1/ko not_active Expired - Fee Related
- 2016-11-16 NZ NZ743236A patent/NZ743236A/en not_active IP Right Cessation
- 2016-11-16 RU RU2018122755A patent/RU2714428C2/ru active
- 2016-11-16 MA MA049414A patent/MA49414A/fr unknown
- 2016-11-16 CA CA3006078A patent/CA3006078A1/en active Pending
- 2016-11-16 AU AU2016361305A patent/AU2016361305B2/en not_active Ceased
- 2016-11-16 CN CN201680075080.4A patent/CN108367067B/zh active Active
- 2016-11-16 DK DK16813258.7T patent/DK3380119T3/da active
- 2016-11-16 WO PCT/US2016/062367 patent/WO2017091418A1/en not_active Ceased
- 2016-11-16 MX MX2018006347A patent/MX382535B/es unknown
- 2016-11-16 MA MA42640A patent/MA42640B1/fr unknown
- 2016-11-16 US US15/353,727 patent/US9913891B2/en active Active
- 2016-11-16 BR BR112018010494A patent/BR112018010494A8/pt not_active IP Right Cessation
- 2016-11-16 ES ES16813258T patent/ES2899230T3/es active Active
- 2016-11-16 JP JP2018545561A patent/JP6797206B2/ja not_active Expired - Fee Related
- 2016-11-16 MA MA043310A patent/MA43310A/fr unknown
- 2016-11-16 EP EP19167578.4A patent/EP3539566A1/en active Pending
- 2016-11-16 EP EP16813258.7A patent/EP3380119B1/en active Active
- 2016-11-23 AR ARP160103584A patent/AR106792A1/es unknown
- 2016-11-23 TW TW105138385A patent/TWI744260B/zh not_active IP Right Cessation
- 2016-11-23 UY UY0001036995A patent/UY36995A/es not_active Application Discontinuation
2018
- 2018-02-05 US US15/888,718 patent/US10363300B2/en active Active
- 2018-05-22 ZA ZA2018/03390A patent/ZA201803390B/en unknown
2020
- 2020-08-06 JP JP2020133788A patent/JP2020203890A/ja active Pending

Also Published As

Publication number	Publication date
US20180169216A1 (en)	2018-06-21
ZA201803390B (en)	2019-03-27
US10363300B2 (en)	2019-07-30
BR112018010494A2 (pt)	2018-11-13
US20170143819A1 (en)	2017-05-25
RU2018122755A (ru)	2019-12-26
KR20180084995A (ko)	2018-07-25
AU2016361305A1 (en)	2018-06-28
WO2017091418A1 (en)	2017-06-01
EP3539566A1 (en)	2019-09-18
CN108367067A (zh)	2018-08-03
TW201726708A (zh)	2017-08-01
CN108367067B (zh)	2022-05-03
HK1258695A1 (en)	2019-11-15
EP3380119A1 (en)	2018-10-03
MA42640B1 (fr)	2021-06-30
MX2018006347A (es)	2019-02-20
RU2018122755A3 (da)	2019-12-26
KR102153303B1 (ko)	2020-09-09
MA49414A (fr)	2020-04-22
JP2019500409A (ja)	2019-01-10
NZ743236A (en)	2019-12-20
JP2020203890A (ja)	2020-12-24
EP3380119B1 (en)	2021-08-25
TWI744260B (zh)	2021-11-01
MA42640A1 (fr)	2019-05-31
MA43310A (fr)	2021-04-28
US9913891B2 (en)	2018-03-13
BR112018010494A8 (pt)	2019-02-26
RU2714428C2 (ru)	2020-02-14
CA3006078A1 (en)	2017-06-01
ES2899230T3 (es)	2022-03-10
MX382535B (es)	2025-03-13
UY36995A (es)	2017-06-30
AR106792A1 (es)	2018-02-21
AU2016361305B2 (en)	2020-02-06
JP6797206B2 (ja)	2020-12-09

Publication	Publication Date	Title
IL262652A (en)	2018-12-31	Gdf15 fusion proteins and uses thereof
IL254165A0 (en)	2017-10-31	Immunomodulatory fusion proteins and uses thereof
DK3292141T3 (da)	2020-04-20	Fusionsproteiner
IL255697A (en)	2018-01-31	Compositions and methods for tcr reprogramming using fusion proteins
ZA201801640B (en)	2019-01-30	Gitrl fusion proteins and uses thereof
DK3280727T3 (da)	2021-03-15	Enkeltarmede type i- og type ii-receptorfusionsproteiner og anvendelser deraf
IL246921B (en)	2019-09-26	Binding proteins and methods of use thereof
DK4234581T3 (da)	2025-10-06	Terapeutiske antistoffer og deres anvendelse
DK3275895T3 (da)	2021-09-27	Neuropilin-1-specifikt bindingspeptid, fusionsprotein fusioneret dermed, og anvendelse deraf
DK3180363T3 (da)	2019-11-04	Sirp-alpha-immunoglobulin fusionsproteiner
DK3303379T3 (da)	2021-12-06	Tigit-bindende midler og anvendelser deraf
DK3268470T3 (da)	2021-02-22	Transposasepolypeptider og anvendelser deraf
HRP20190028T1 (hr)	2019-02-22	Interleukin-2 fuzijski proteini i njihove primjene
DK3412302T3 (da)	2021-07-12	Modificerede fgf-21-polypeptider og anvendelser deraf
DK3368655T3 (da)	2020-09-14	Forbedret proteinekspression og fremgangsmåder dertil
EP3188758C0 (en)	2023-10-04	SIRP ALPHA-ANTIBODY FUSION PROTEIN
DK3532499T3 (da)	2021-06-28	ANTI-IL-33-antistoffer og anvendelser deraf
DK3498292T3 (da)	2022-01-03	Uspa2-proteinkonstruktioner og anvendelser deraf
DK3322734T3 (da)	2020-10-26	Multivalente og multispecifikke DR5-bindende fusionsproteiner
DK3402821T5 (da)	2024-09-23	Psma-bindende antistof og anvendelser deraf
DK3107562T3 (da)	2019-12-16	P97-ids-fusionsproteiner
DK3380119T3 (da)	2021-11-15	Fmdv- og e2-fusionsproteiner og anvendelser deraf
EP3344278A4 (en)	2019-01-23	INSULIN-IMMUNOGLOBULIN FUSION PROTEINS
IL250796A0 (en)	2017-04-30	Binding proteins specific for lox1 and uses thereof
DK3290441T3 (da)	2020-01-02	Rgma-bindingsprotein og anvendelse deraf